Background: Evidence suggests the positive effects of ketogenic diet (KD) on cancers by limiting glucose availability to cancer cells. This systematic review aimed to explore the safety, feasibility, and effectiveness of KD in children with brain tumors including diet side effects, patient tolerance and compliance, tumor response, quality of life, and nutritional status. Methods: Six databases were searched for relevant publications between 1995 and 2022; non‐English language publications were excluded to avoid misinterpretation. The Joanna Briggs Institute assessment scale for observational studies was used to measure study methodology quality and evaluate the extent to which the bias possibility in study design, conduct, and analysis has been stated. The study was registered in PROSPERO under registration number (CRD42021281620). Results: Ultimately, eight eligible publications involving a total of 11 children with brain tumors following KD were included. Nine patients followed classic KD with medium‐chain triglyceride oil, whereas others followed a modified Atkin or low‐carbohydrate diet. KD was well‐tolerated, having nonsevere side effects. Six patients showed positive tumor response, five improved neurological skills, and four reported growth improvement. Six patients reported a median overall survival of 17.6 months. Lastly, statistical analyses could not be performed; hence, a meta‐analysis was not possible. Conclusion: KD may be a safe and feasible dietary intervention for children with brain tumors. However, the effects on tumors remain unclear and require further study. The study limitation included the lack of high‐quality and appropriately controlled trials with large samples. Moreover, heterogeneity was observed, and quality‐of‐life assessments were self‐reported, which might have resulted in bias or inaccuracy.
Background/objectives: Treating pediatric brain tumors remains challenging due to the limitations of conventional therapies, which often damage healthy cells. Ketogenic diets (KDs)—high in fat and low in carbohydrates—have emerged as potential adjunct therapies by limiting glucose availability and offering ketones as an alternative energy source proposed to hinder tumor growth. However, due to limited awareness, there is hesitancy to recommend KDs. Methods: This study assessed oncologists’ knowledge and perceptions in Saudi Arabia regarding KD use in pediatric brain cancer patients. A cross-sectional survey was conducted with 94 oncologists from five major Riyadh healthcare centers, examining their knowledge, safety concerns, feasibility, and perceived efficacy of KDs. Results: Results showed that 67% correctly identified the basic composition of KDs, though 43% were neutral about its safety. Concerns about malnutrition and side effects were common and 53% found adherence to the diet challenging in pediatric patients. While 48.9% believed KDs could improve outcomes when combined with standard therapies, many stressed the importance of tailoring recommendations to individual medical conditions, including patient age, treatment stage, and overall nutritional status. Participants’ responses revealed variability in knowledge and perception levels regarding KDs, with consultants and internationally educated oncologists generally expressing more favorable views compared to fellows, who showed greater hesitancy. Conclusions: This study shows a mixed level of knowledge and perceptions among oncologists, reflecting a lack of consensus about KDs’ safety, feasibility, and potential benefits. These findings suggest the need for further education, clearer guidelines, and interdisciplinary collaboration to support informed decision-making, particularly in the local context.